JP2002509712A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002509712A5 JP2002509712A5 JP2000541199A JP2000541199A JP2002509712A5 JP 2002509712 A5 JP2002509712 A5 JP 2002509712A5 JP 2000541199 A JP2000541199 A JP 2000541199A JP 2000541199 A JP2000541199 A JP 2000541199A JP 2002509712 A5 JP2002509712 A5 JP 2002509712A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- seq
- cells
- patient
- amino acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 description 25
- 108090000765 processed proteins & peptides Proteins 0.000 description 25
- 102000004196 processed proteins & peptides Human genes 0.000 description 25
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 15
- 101000884270 Homo sapiens Natural killer cell receptor 2B4 Proteins 0.000 description 15
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 13
- 102100036008 CD48 antigen Human genes 0.000 description 11
- 150000007523 nucleic acids Chemical class 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 102000048338 human CD244 Human genes 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 102000046585 human CD48 Human genes 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000003158 yeast two-hybrid assay Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7984598P | 1998-03-27 | 1998-03-27 | |
| US60/079,845 | 1998-03-27 | ||
| US9675098P | 1998-08-17 | 1998-08-17 | |
| US60/096,750 | 1998-08-17 | ||
| PCT/US1999/006215 WO1999050297A1 (en) | 1998-03-27 | 1999-03-23 | Nk cell activation inducing ligand (nail) dna and polypeptides, and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002509712A JP2002509712A (ja) | 2002-04-02 |
| JP2002509712A5 true JP2002509712A5 (https=) | 2006-05-18 |
Family
ID=26762494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000541199A Pending JP2002509712A (ja) | 1998-03-27 | 1999-03-23 | Ｎｋ細胞活性化誘導リガンド（ｎａｉｌ）ｄｎａおよびポリペプチド、並びにそれらの使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20080081043A1 (https=) |
| EP (1) | EP1064307A1 (https=) |
| JP (1) | JP2002509712A (https=) |
| AU (1) | AU744150B2 (https=) |
| CA (1) | CA2323524A1 (https=) |
| IL (2) | IL138410A0 (https=) |
| NZ (1) | NZ507641A (https=) |
| WO (1) | WO1999050297A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000073333A2 (en) * | 1999-05-28 | 2000-12-07 | Immunex Corporation | Ligand for cd7, and methods for use thereof |
| IL160157A0 (en) | 2001-08-17 | 2004-07-25 | Coley Pharm Group Inc | Combination motif immune stimulation oligonucleotides with improved activity |
| CN106103701B (zh) * | 2014-01-03 | 2020-04-24 | 中央研究院 | 改造的自然杀手细胞及其组成与用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| US5688690A (en) * | 1994-09-16 | 1997-11-18 | The Wistar Institute Of Anatomy And Biology | Human cytotoxic lymphocyte signal transduction surface protein (P38) and monoclonal antibodies thereto |
| WO2013128474A1 (en) | 2012-03-02 | 2013-09-06 | Council Of Scientific & Industrial Research | Double fortified salt composition containing iron and iodine and process for the preparation thereof |
-
1999
- 1999-03-23 IL IL13841099A patent/IL138410A0/xx not_active IP Right Cessation
- 1999-03-23 NZ NZ507641A patent/NZ507641A/en unknown
- 1999-03-23 JP JP2000541199A patent/JP2002509712A/ja active Pending
- 1999-03-23 AU AU31970/99A patent/AU744150B2/en not_active Ceased
- 1999-03-23 WO PCT/US1999/006215 patent/WO1999050297A1/en not_active Ceased
- 1999-03-23 CA CA002323524A patent/CA2323524A1/en not_active Abandoned
- 1999-03-23 EP EP99914030A patent/EP1064307A1/en not_active Withdrawn
-
2000
- 2000-09-12 IL IL138410A patent/IL138410A/en unknown
-
2007
- 2007-07-03 US US11/824,835 patent/US20080081043A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Miura et al. | Molecular cloning of nucleobindin, a novel DNA-binding protein that contains both a signal peptide and a leucine zipper structure | |
| AU653387B2 (en) | Antigen-presenting chimaeric protein | |
| CN112399854B (zh) | 预防或治疗严重发热伴血小板减少综合征(sfts)病毒性感染所致疾病的疫苗组合物 | |
| JPH09322781A5 (https=) | ||
| JP2006515749A5 (https=) | ||
| WO2001021810B1 (en) | Chlamydia antigens and corresponding dna fragments and uses thereof | |
| RU2003130638A (ru) | Протеин, связанный с заболеванием | |
| CN108840951A (zh) | 一种由猪白蛋白、猪干扰素γ和猪干扰素α组成的融合蛋白及其制备方法 | |
| JP2003525619A (ja) | ウイルスコートタンパク質融合体としての植物における外来ポリペプチドの産生 | |
| Green et al. | Human adenovirus 2 E1B-19K and E1B-53K tumor antigens: antipeptide antibodies targeted to the NH2 and COOH termini | |
| CN107353346A (zh) | 一种由猪白蛋白与猪干扰素γ组成的融合蛋白及其制备方法和一种重组猪长效干扰素γ | |
| JP2003514576A5 (https=) | ||
| JP2004532037A5 (https=) | ||
| CN100588430C (zh) | 基于表位的SARS-Cov基因疫苗及其构建 | |
| JPH10500009A (ja) | Ｈｃｍｖおよびｈｓｖ由来の融合糖蛋白質 | |
| JP2002509712A5 (https=) | ||
| KR102542601B1 (ko) | 신규한 돼지 유행성 설사병 바이러스 및 이의 용도 | |
| CN108840950A (zh) | 一种由猪白细胞介素2、猪干扰素γ和猪干扰素α组成的融合蛋白及其制备方法 | |
| CA2365196A1 (en) | Chlamydia antigens and corresponding dna fragments and uses thereof | |
| JP2003507029A5 (https=) | ||
| CN108840945A (zh) | 猪白蛋白-干扰素α-白介素2融合蛋白、制备方法及其编码基因、一种猪长效干扰素 | |
| GB2079288A (en) | DNA Sequences, Recombinant DNA Molecules and Processes for Producing Polypeptides with the Specificity of Foot and Mouth Disease Viral Antigens | |
| JP6756950B2 (ja) | ヒトヘルペスウイルス６ｂ抗原組成物 | |
| JP2002523046A5 (https=) | ||
| JP2004518410A5 (https=) |